Analyst Downgrades: GoPro Inc, Valeant Pharmaceuticals Intl Inc, and Apple Inc.

Analysts downwardly revised their ratings on GoPro Inc (NASDAQ:GPRO), Valeant Pharmaceuticals Intl Inc (NYSE:VRX), and Apple Inc. (NASDAQ:AAPL)

Dec 14, 2015 at 9:29 AM
facebook twitter linkedin


Analysts are weighing in on action camera maker GoPro Inc (NASDAQ:GPRO), drugmaker Valeant Pharmaceuticals Intl Inc (NYSE:VRX), and tech titan Apple Inc. (NASDAQ:AAPL)Here's a quick roundup of today's bearish brokerage notes on GPRO, VRX, and AAPL.

  • GPRO is set to drop 6% this morning, after the shares were hit with another downgrade. This time it was Morgan Stanley who weighed in, reducing its outlook to "underweight" from "equal weight," and slashing its price target to $12 from $23. More downgrades could be forthcoming for GoPro Inc, since the majority of analysts still rate it a "buy" or better. The equity has dropped almost 70% in 2015, settling at $19.15 on Friday. 
  • VRX is edging higher in pre-market trading, even though RBC cut its price target to $194 from $206. Then again, this still represents more than twice the security's current level, last seen at $93.06. The stock has dropped over 57% in the past three months in the wake of Citron Research's short-seller report. As a result, Valeant Pharmaceuticals Intl Inc has reportedly hired an attorney, as well as public relations specialists. Option traders are hoping the shares can make up some of their lost ground. VRX's 10-day call/put volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) stands at 2.75, which ranks higher than 89% of all comparable readings from the past year. 
  • AAPL got hit with a price-target cut to $150 from $155 at Barclays, and is now looking at a 1.3% drop out of the gate. In addition, Morgan Stanley trimmed its target to $143 from $152, citing an expected drop in iPhone unit sales. The shares closed last week at $113.18, hanging on to a 2.5% year-to-date lead. Most other analysts maintain a bullish outlook for Apple Inc. Twenty-two of the 31 brokerage firms with coverage on the stock say it's a "buy" or better, and AAPL's average 12-month price target of $148.31 stands in never-before-charted territory. 
 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial
 


 


 
Special Offers from Schaeffer's Trading Partners